Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: Data from a randomised placebo controlled trial of lamotrigine

Journal of Neurology

Volumn 259, Issue 3, 2012, Pages 505-514

  Hayton, T ^a   Furby, J ^a   Smith, K J ^a   Altmann, D R ^b   Brenner, R ^c   Chataway, J ^d   Hunter, K ^a   Tozer, D J ^a   Miller, D H ^a   Kapoor, R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

MRI; MSFC; MTR; Multiple sclerosis; Secondary progressive

Indexed keywords

LAMOTRIGINE;

ADULT; AGED; ARTICLE; BRAIN SIZE; BRAIN TISSUE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXPANDED DISABILITY STATUS SCALE; FEMALE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT; PHYSICIAN; PRIORITY JOURNAL; WHITE MATTER;

ADULT; CALCIUM CHANNEL BLOCKERS; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRIAZINES;

EID: 84862568917     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6212-9     Document Type: Article

References (44)

1. Wolff SD, Balaban RS (1989) Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med 10:135-144 (Pubitemid 19107973)
2. van Waesberghe JHTM, Kamphorst W, de Groot CJA, van Walderveen MAA, Castelijns JA, Ravid R, Lycklama a Nijeholt GJ, van der Valk P, Polman CH, Thompson AJ, Barkhof F (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747-754 (Pubitemid 29518136)
3. Schmierer K, Scaravelli F, Altmann DR, Barker GJ, Miller DH (2004) Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 56:407-415 (Pubitemid 39166560)
4. Davie CA, Silver NC, Barker GJ, Tofts PS, Thompson AJ, McDonald WI, Miller DH (1999) Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neuro Neurosurg Psychiatr 67:710-715
5. Kutzelnigg A, Luchinetti CF, Stadelman C, Bruck W, Rauschka H, Bermann M, Schmidbauer M, Parisi JE, Lassman H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705-2712 (Pubitemid 41552953)
6. Bechtold DA, Miller SJ, Dawson AC, Sun Y, Kapoor R, Berry D, Smith KJ (2006) Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 253:1542-1551 (Pubitemid 46115434)
7. Moll NM, Cossoy MB, Fisher E, Staugaitis SM, Tucky BH, Rietsch AM, Chang A, Fox RJ, Trapp BD, Ransohoff RM (2009) Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 66:44-53
8. Smith KJ, Kapoor R, Hall SM, Davies M (2001) Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 49:470-476 (Pubitemid 32281330)
9. Craner MJ, Lo AC, Black JA, Waxman SG (2003) Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. Brain 126:1552-1556
10. Stys PK, Waxman SG, Ransom BR (1992) Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na? channels and Na(?)-Ca2? exchanger. J Neurosci 12:430-439
11. Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ (2003) Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 53:174-180 (Pubitemid 36163998)
12. Bechtold DA, Smith KJ (2005) Sodium mediated axonal degeneration in inflammatory demyelinating disease. J Neurol Sci 233:27-35 (Pubitemid 40804813)
13. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DA, Brenner R, Chataway J, Hughes RAC, Miller DH (2010) A randomized controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis. Lancet Neurol 9:681-688
14. Altmann, Jasperse B, Barkhof F, Beckmann K, Filippi M, Kappos LD, Molyneux P, Polman CH, Pozzilli C, Thompson AJ, Wagner K, Yousry TA, Miller DH (2009) Sample sizes for brain atrophyoutcomes in trials for secondary progressive multiple sclerosis. Neurology 72:595-601
15. Ashburner J, Friston KJ (2005) Unified segmentation. NeuroImage 26:839-851 (Pubitemid 40825026)
16. Evans AC, Collins DL, Mills SR, Brown ED, Kelly RL, Peters TM (1993) 3D statistical neuroanatomical models from 305 MRI volumes. In: Proceedings IEEE-Nuclear Science Symposium and Medical Imaging Conference, pp 1813-1817
17. Dehmeshki J, Ruto AC, Arridge S, Silver NC, Miller DH, Tofts PS (2001) Analysis of MTR histograms in multiple sclerosis using principle components and multiple discriminant analysis. Magn Reson Med 46:600-609 (Pubitemid 32831337)
18. Robiner WN (2005) Enhancing adherence in clinical trials. Contemp Clin Trials 26:59-77
19. Bruce JM, Hancock LM, Lynch SG (2010) Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult Scler 16:112-120
20. Barkhof F, Bruck W, De Groot CJA, Bergers E, Hulsof S, Geurts J, Polman CH (2003) Remyelinated lesions in multiple sclerosis. Arch Neurol 60:1073-1081
21. Vrenken H, Guerts JJG, Knol DL, Polman CH, Castelijns JS, Pouwels PJW, Barkhof F (2006) Normal appearing white matter changes vary with distance to lesions in multiple sclerosis. Am J Neuroradiol 27:2005-2011 (Pubitemid 44556526)
22. Fisher E, Chang A, Fox RJ, Tkach JA, Svarovsky T, Nakamura K, Rudick RA, Trapp BD (2007) Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 62:219-228 (Pubitemid 47525397)
23. Young EA, Fowler CD, Kidd GJ, Chang A, Rudick R, Fisher E, Trapp BD (2008) Imaging correlates of decreased axonal Na?/K? ATPase in chronic multiple sclerosis lesions. Ann Neurol 63: 428-435 (Pubitemid 351614708)
24. Rocca MA, Mastronardo G, Rodegher M, Comi G, Filippi M (1999) Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. Am J Neuroradiol 20:821-827 (Pubitemid 29536257)
25. Inglese M, van Easberghe JHTM, Rovaris M, Beckmann K, Barkhof F, Hahn D, Kappos L, Miller DH, Polman C, Pozilli C, Thompson AJ, Yousry TA, Wagner K, Comi C, Filippi M (2003) The effect of interferon b-1b on quantities derived from MT MRI in secondary progressive MS. Neurology 60:853-860 (Pubitemid 36297373)
26. Rovaris M, Agosta F, Sormani MP, Inglese M, Martinelliu V, Comi G, Filippi M (2003) Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. Brain 126:2323-2332 (Pubitemid 37432375)
27. Inglese M, Horsfield A, Filippi M (2001) Scan-rescan variation of measures derived from brain magnetization transfer ratio histograms obtained in healthy volunteers by use of a semi-interleaved magnetization transfer sequence. AJNR Am J Neuroradiol 22: 681-684 (Pubitemid 32318696)
28. Chard DT, Parker GJM, Griffin CMB, Thompson AJ, Miller DH (2002) The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J Magn Reson Imaging 5:259-267 (Pubitemid 34195121)
29. Hayton T, Furby J, Smith KJ, Altmann, Brenner R, Chataway J, Hughes RAC, Hunter K, Tozer D, Miller DH, Kapoor R (2009) Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol 256:427-435
30. Rovaris M, Filippi M, Minicucci L, Iannucci G, Santuccio G, Possa F, Comi G (2000) Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol 21:402-408 (Pubitemid 30102175)
31. Ramio-Torrenta L, Sastre Garriga J, Ingle GT, Davies GR, Ameen V, Miller DH, Thompson AJ (2006) Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatr 77:40-45 (Pubitemid 43022688)
32. Deloire MS, Salort E, Bonnet M, Arimone Y, Boudineau M, Amieva H, Barroso B, Ouallet JC, Pachai C, Galliaud E, Petry KG, Dousset V, Fabrigoule C, Brochet B (2005) Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatr 76:519-526 (Pubitemid 40486577)
33. Davies GR, Ramio-Torrenta L, Hadjiprocopis A, Chard DT, Griffin CMB, Rashid W, Barker GJ, Kapoor R, Thompson AJ, Miller DH (2004) Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatr 75:998-1002 (Pubitemid 38869614)
34. Filippi M, Inglese M, Rovaris M, Sormani MP, Horsfield G, Iannucci G, Colombo B, Comi G (2000) Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up. Neurology 55:940-946
35. Amato MP, Portaccio E, Goretti B, Zipoli V, Battaglini M, Bartolozzi ML, Stromillo ML, Guidi L, Siracusa G, Sorbi S, Federico A, De Stefano N (2007) Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 64:1157-1161 (Pubitemid 47258075)
36. Sanfilipo MP, Benedict RH, Weinstock-Guttman B, Bakshi R (2006) Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 66:685-692 (Pubitemid 43739822)
37. Morgen K, Sammer G, Courtney SM, Wolters T, Melchior H, Blecker CR, Oschmann P, Kaps M, Vaitl D (2006) Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. Neuroimage 30:891-898
38. Sastre-Garriga J, Arévalo MJ, Renom M, Alonso J, González I, Galán I, Montalban X, Rovira A (2009) Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis. J Neurol Sci 282:120-124
39. Fisniku LK, Cercignani M, Tozer D, Chard D, Jackson J, Miszkiel K, Schmierer K, Thompson A, Miller D (2009) Magnetisation transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis. Mult Scler 15:668-677
40. Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M (2006) Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 129:2620-2627 (Pubitemid 44522095)
41. Losseff NA, Wang L, Lau HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119:2009-2019
42. Furby J, Hayton T, Altmann D, Brenner R, Chataway J, Hughes RAC, Smith KJ, Miller DH, Kapoor R (2010) A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol 257:1508-1516
43. van del Elksamp IJ, Knol DL, Vrenken H, Karas G, Meijerman A, Filippi M, Kappos L, Fazekas F, Wagner K, Pohl C, Sandbrink R, Polman CH, Uitdehaag BMJ, Barkhof F (2010) Lesional magnetization transfer ratio a feasible outcome for remyelinating trials in multiple sclerosis. Mult Scler 16:660-669
44. Zivadinov R, Reder AT, Filippi M, Minagar A, Stüve O, Lassmann H, Racke MK, Dwyer MG, Frohman EM, Khan O (2008) Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71:136-144